How to Read a Peptide Study Without Getting Fooled

A single study almost never settles anything, yet one cherry-picked abstract is often all it takes to sell a compound. Here is how to read the evidence behind a peptide claim the way we do when we assign an evidence grade — and where the usual tricks hide.

Who (or what) was actually studied

The first question is what kind of subject the study used, because that single fact caps how much it can tell you.

• In vitro vs. in vivo. A peptide that does something to cells in a dish (in vitro) hasn’t been shown to do anything in a living body. Useful for mechanism; not evidence of a real-world effect.
• Animal vs. human. This is the big one. Roughly 9 in 10 drug candidates that enter clinical trials never reach approval, and most of that failure is a failure to work or to be safe in people — the single largest share being drugs that simply aren’t effective at a tolerable dose. A mountain of glowing rat data is a hypothesis, not a result. On our scale it tops out at Animal only.
• Anecdote vs. trial. Forum reports and influencer testimonials aren’t data. Without a comparison group, you can’t separate the compound from placebo, regression to the mean, or everything else the person changed.

How the study was designed

Among human studies, design determines weight.

• RCT (randomized controlled trial): participants are randomly assigned to treatment or control, ideally with blinding (neither subject nor researcher knows who got what) and a placebo. Randomization and blinding are what keep wishful thinking and the placebo effect out of the result. This is the basis for our Strong human grade.
• Observational study: researchers watch what happens without assigning treatment. Useful for generating hypotheses, but prone to confounding — the people who choose a treatment differ from those who don’t.
• Sample size and duration. Ten people for four weeks can’t tell you about a 1% adverse event or a year-long outcome. Small, short, or unreplicated human trials are exactly what we mean by Preliminary human: suggestive, not settled.

What was actually measured

A study can be flawless and still answer the wrong question. Watch the endpoint.

A surrogate endpoint is a lab value or scan thought to predict benefit — a hormone level, a marker on a blood panel. A real-world (clinical) endpoint is whether people actually felt better, functioned better, or lived longer. The FDA itself defines a surrogate as a marker “thought to predict clinical benefit but is not itself a measure of clinical benefit.” Surrogates often don’t pan out: in a systematic review of oncology trials, most surrogate measures showed only a low correlation with actual survival. “Raised IGF-1” or “improved a biomarker” is not the same as “made anyone healthier.”

Who ran it, and where it appeared

Two final filters that catch a lot of hype.

• Conflicts of interest and single-lab concentration. Industry-funded trials are measurably more likely to report favorable results and favorable conclusions than independent ones (a large Cochrane review documented this). And when nearly all the positive research on a compound traces to one lab with no independent replication, treat it as unconfirmed — a point we flag explicitly in our methodology.
• Preprint vs. peer-reviewed; press release vs. publication. A preprint hasn’t been peer-reviewed yet; medRxiv itself warns that preprints “should not be relied on to guide clinical practice.” A company press release is marketing — it may describe a trial you can’t read, with no methods, data, or independent scrutiny. Until there’s a published, peer-reviewed paper you can actually check, the claim is provisional.

Bottom line

Run any peptide study through the same questions: Was it humans or animals, in a body or a dish? Randomized, controlled, blinded — or just observed? Big and long enough to mean something? Did it measure a real outcome or a surrogate? Who funded it, did anyone replicate it, and is it actually published? Those answers are exactly what separate Strong human from Animal only from No credible evidence in our grades. When the evidence is thin, the honest move is to say so — not to round up to a headline.

Educational content only. Not medical advice.

Sources

• FDA Facts: Biomarkers and Surrogate Endpoints (U.S. Food & Drug Administration)
• Surrogate Endpoint Resources for Drug and Biologic Development (U.S. Food & Drug Administration)
• Prasad V, et al. The Strength of Association Between Surrogate End Points and Survival in Oncology. JAMA Internal Medicine, 2015
• Lundh A, et al. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews, 2017
• What is an unrefereed preprint? (medRxiv)
• Preprints: peer review and PubMed Central (U.S. National Library of Medicine)